Další formáty:
BibTeX
LaTeX
RIS
@proceedings{2357977,
author = {Peschelová, Helena and Kozlová, Veronika and Mančíková, Veronika and Dostálová, Lenka and Ladungová, Adriana and Škrnová, Dominika and Hejret, Václav and Šmída, Michal},
booktitle = {PhD and PostDoc RETREAT, Sněžné, Milovy},
keywords = {Chronic lymphocytic leukemia; somatic mutations; CRISPR/Cas9 screening},
language = {eng},
title = {CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia.},
url = {https://www.ceitec.eu/ceitec-phd-conference-2023/a4489},
year = {2023}
}
TY - CONF
ID - 2357977
AU - Peschelová, Helena - Kozlová, Veronika - Mančíková, Veronika - Dostálová, Lenka - Ladungová, Adriana - Škrnová, Dominika - Hejret, Václav - Šmída, Michal
PY - 2023
TI - CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia.
KW - Chronic lymphocytic leukemia
KW - somatic mutations
KW - CRISPR/Cas9 screening
UR - https://www.ceitec.eu/ceitec-phd-conference-2023/a4489
N2 - Chronic lymphocytic leukemia (CLL) is characterized by genetic heterogeneity and a variety of somatic mutations, the most frequent of which targeting ATM, TP53, NOTCH1, MYD88 and SF3B1 genes. A thorough exploration of these mutations could shed light on the disease etiology, or even lead to the discovery of potential novel drug targets. However, CLL cells extracted from patients do not proliferate ex vivo and thus preclude lengthy experiments, such as CRISPR/Cas9 screening. 76 The aim of this study was to generate stable knockout (ATM, TP53) and knock-in (NOTCH1, SF3B1 and MYD88) CLL cell lines and subsequently use them to investigate unique vulnerabilities specific to these mutations
ER -
PESCHELOVÁ, Helena, Veronika KOZLOVÁ, Veronika MANČÍKOVÁ, Lenka DOSTÁLOVÁ, Adriana LADUNGOVÁ, Dominika ŠKRNOVÁ, Václav HEJRET a Michal ŠMÍDA. CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia. In \textit{PhD and PostDoc RETREAT, Sněžné, Milovy}. 2023.
|
